455 related articles for article (PubMed ID: 30785608)
1. Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia.
Tiihonen J; Taipale H; Mehtälä J; Vattulainen P; Correll CU; Tanskanen A
JAMA Psychiatry; 2019 May; 76(5):499-507. PubMed ID: 30785608
[TBL] [Abstract][Full Text] [Related]
2. Real-world effectiveness of antipsychotic monotherapy vs. polypharmacy in schizophrenia: to switch or to combine? A nationwide study in Hungary.
Katona L; Czobor P; Bitter I
Schizophr Res; 2014 Jan; 152(1):246-54. PubMed ID: 24275583
[TBL] [Abstract][Full Text] [Related]
3. Comparative effectiveness of antipsychotic monotherapy and polypharmacy in schizophrenia patients with clozapine treatment: A nationwide, health insurance data-based study.
Joo SW; Kim H; Jo YT; Ahn S; Choi YJ; Choi W; Park S; Lee J
Eur Neuropsychopharmacol; 2022 Jun; 59():36-44. PubMed ID: 35550204
[TBL] [Abstract][Full Text] [Related]
4. Outcomes of medicaid beneficiaries with schizophrenia receiving clozapine only or antipsychotic combinations.
Velligan DI; Carroll C; Lage MJ; Fairman K
Psychiatr Serv; 2015 Feb; 66(2):127-33. PubMed ID: 25321616
[TBL] [Abstract][Full Text] [Related]
5. Real-World Evidence of Antipsychotic Monotherapy Versus Polypharmacy in the Treatment of Schizophrenia Spectrum Disorders.
Korkmaz ŞA; Koca E; Yilmaz Ö; Özbek T; Güçlü MA; Kizgin S
J Clin Psychopharmacol; 2024 May-Jun 01; 44(3):250-257. PubMed ID: 38489589
[TBL] [Abstract][Full Text] [Related]
6. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia.
Tiihonen J; Haukka J; Taylor M; Haddad PM; Patel MX; Korhonen P
Am J Psychiatry; 2011 Jun; 168(6):603-9. PubMed ID: 21362741
[TBL] [Abstract][Full Text] [Related]
7. Beneficial Effects of Concomitant Long-Acting Injectable Antipsychotics on Time to Rehospitalization in Patients With Treatment-Resistant Schizophrenia Receiving Clozapine: A Retrospective Cohort Study.
Tien Y; Wang XY; Huang SC; Huang HP
J Clin Psychiatry; 2024 May; 85(2):. PubMed ID: 38696112
[No Abstract] [Full Text] [Related]
8. Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials.
Correll CU; Rummel-Kluge C; Corves C; Kane JM; Leucht S
Schizophr Bull; 2009 Mar; 35(2):443-57. PubMed ID: 18417466
[TBL] [Abstract][Full Text] [Related]
9. Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: experience in a multistate Medicaid population, 1998-2003.
Morrato EH; Dodd S; Oderda G; Haxby DG; Allen R; Valuck RJ
Clin Ther; 2007 Jan; 29(1):183-95. PubMed ID: 17379060
[TBL] [Abstract][Full Text] [Related]
10. Schizophrenia patients discharged on antipsychotic polypharmacy from a public psychiatric hospital in Taiwan, 2006-2021.
Lin CH; Huang CJ; Lin TC; Chan HY; Chen JJ
Psychiatry Res; 2023 Dec; 330():115575. PubMed ID: 37913621
[TBL] [Abstract][Full Text] [Related]
11. Safety of Antipsychotic Polypharmacy Versus Monotherapy in a Nationwide Cohort of 61,889 Patients With Schizophrenia.
Taipale H; Tanskanen A; Tiihonen J
Am J Psychiatry; 2023 May; 180(5):377-385. PubMed ID: 36945825
[TBL] [Abstract][Full Text] [Related]
12. The risks and benefits of switching patients with schizophrenia or schizoaffective disorder from two to one antipsychotic medication: a randomized controlled trial.
Constantine RJ; Andel R; McPherson M; Tandon R
Schizophr Res; 2015 Aug; 166(1-3):194-200. PubMed ID: 26141142
[TBL] [Abstract][Full Text] [Related]
13. Antipsychotic Polypharmacy for the Management of Schizophrenia: Evidence and Recommendations.
Lähteenvuo M; Tiihonen J
Drugs; 2021 Jul; 81(11):1273-1284. PubMed ID: 34196945
[TBL] [Abstract][Full Text] [Related]
14. Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000.
Ganguly R; Kotzan JA; Miller LS; Kennedy K; Martin BC
J Clin Psychiatry; 2004 Oct; 65(10):1377-88. PubMed ID: 15491242
[TBL] [Abstract][Full Text] [Related]
15. One Plus One Sometimes Equals More Than Two: Long-acting Injectable Aripiprazole Adjunction in Clozapine-Resistant Schizophrenia.
Balcioglu YH; Gokcay H; Yesilkaya UH
Clin Neuropharmacol; 2020; 43(5):166-168. PubMed ID: 32947430
[TBL] [Abstract][Full Text] [Related]
16. Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia in routine clinical care: a randomized, controlled trial.
Barbui C; Accordini S; Nosè M; Stroup S; Purgato M; Girlanda F; Esposito E; Veronese A; Tansella M; Cipriani A;
J Clin Psychopharmacol; 2011 Jun; 31(3):266-73. PubMed ID: 21508849
[TBL] [Abstract][Full Text] [Related]
17. Antipsychotic prescribing pathways, polypharmacy, and clozapine use in treatment of schizophrenia.
Gören JL; Meterko M; Williams S; Young GJ; Baker E; Chou CH; Kilbourne AM; Bauer MS
Psychiatr Serv; 2013 Jun; 64(6):527-33. PubMed ID: 23450334
[TBL] [Abstract][Full Text] [Related]
18. [Antipsychotic polypharmacy in high-utilising patients with schizophrenia].
Schmidt-Kraepelin C; Puschner B; Loos S; Janssen B
Psychiatr Prax; 2013 Oct; 40(7):380-4. PubMed ID: 23681790
[TBL] [Abstract][Full Text] [Related]
19. Critical review of antipsychotic polypharmacy in the treatment of schizophrenia.
Fleischhacker WW; Uchida H
Int J Neuropsychopharmacol; 2014 Jul; 17(7):1083-93. PubMed ID: 22717078
[TBL] [Abstract][Full Text] [Related]
20. Predictors of clozapine response in patients with treatment-refractory schizophrenia: results from a Danish Register Study.
Nielsen J; Nielsen RE; Correll CU
J Clin Psychopharmacol; 2012 Oct; 32(5):678-83. PubMed ID: 22926603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
